The effectiveness of using respiratory probiotic Streptococcus salivarius K12 in children with recurrent tonsillitis

Authors

  • S.I. Ilchenko State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine,
  • A.A. Fialkovska State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine,
  • S.H. Ivanus Municipal Non-Profit Enterprise “City Children’s Clinical Hospital 2”, Dnipro, Ukraine,

DOI:

https://doi.org/10.22141/2312-413x.8.2.2020.199732

Keywords:

recurrent tonsillitis, post-streptococcal complications, respiratory probiotic Streptococcus salivarius K12, children

Abstract

Recurrent tonsillitis is common in all age groups, but the highest incidence is observed in the pediatric population due to morphological immaturity of the tonsils and age-related incompleteness of the immunological functions of the child’s body. The most promising direction in the therapy of recurrent tonsillitis today is the use of oral probiotics that inhibit Streptococcus pyogenes, one of the most significant pathogens in the oral cavity. The study showed that the use of Streptococcus salivarius K12 (Bactoblis) in the comprehensive therapy of recurrent tonsillitis for 30 days was characterized by a rapid relief of both local and general manifestations of disease, as well as a significant improvement in the microbiome of the upper respiratory tract. The results obtained indicate the possibility of using Streptococcus salivarius K12 for the prevention of relapse of recurrent tonsillitis and reduction of the incidence of local and general post-streptococcal complications in this category of patients.

References

Андреева И.В., Стецюк О.У. Новый пробиотический штамм Streptococcus salivarius K12 в клинической практике. Клиническая микробиология и антимикробная химиотерапия. 2019. Т. 21. № 2. С. 92-99. DOI: 10.36488/cmac.2019.2.92-99.

Годована О.І., Бежук Ю.А. Перебіг тонзилярної інфекції та захворювань пародонту в світлі окремих аспектів етіології та патогенезу (огляд літератури). Вісник проблем біології і медицини. 2019. Вип. 2. Т. 2 (151). С. 24-29. doi: 10.29254/2077-4214-2019-2-2-151-24-29.

Заплатников А.Л., Гирина А.А., Леписева И.В. К вопросу о рациональной терапии острых респираторных инфекций у детей в условиях растущей антибиотикорезистентности. Педиатрия. Consilium Medicum. 2018. № 4. С. 37-41. doi: 10.26442/24138460.2018.4.180133.

Катосова Л.К., Лазарева А.В., Хохлова Т.А., Пономаренко О.А., Алябьева Н.М. Распространенность и механизмы устойчивости к макролидам Streptococcus pyogenes, выделенных у детей. Антибиотики и химиотерапия. 2016. № 61. С. 23-29.

Крамарев С.А., Евтушенко В.В. Бактоблис® (Streptococcus salivarius K12) — инновационная терапия и профилактика острых респираторных инфекций и их осложнений. Актуальная инфектология. 2019. Т. 7. № 1. С. 39-41.

Крючко Т.О., Ткаченко О.Я. Клінічний досвід застосування Streptococcus salivarius K12 у профілактиці фаринготонзилітів і респіраторних інфекцій у дітей. Здоровье ребенка. 2018. Т. 13. № 7. С. 629-634.

Леженко Г.О., Пашкова О.Є. Раціональний вибір етіо­тропної терапії при запальних захворюваннях лор-органів у дітей. Современная педиатрия. 2016. № 1 (73). С. 44-48.

Машейко А.М., Макаренко О.В., Маврутенков В.В., Слатвицький В.Г. Огляд сучасних аспектів ведення дітей та підлітків, хворих на стрептококовий тонзилофарингіт. Дитячий лікар. 2016. № 1 (46). C. 1-8.

Попович В.И. Новые подходы к классификации и терапии острых тонзиллитов. Здоров’я України 21-го сторіччя. 2016. № 24 (397). С. 41.

Пухлик С.М., Тагунова И.К., Андреев А.В. Роль грибковой инфекции при хроническом воспалении небных миндалин и возможности лечения. Журнал вушних, носових і горлових хвороб. 2016. № 5. С. 74-81.

Bertuccioli A. et al. Streptococcus salivarius K12 in pharyngotonsillitis and acute otitis media — a meta-analysis. Nutrafoods. 2019. № 2. Р. 80-88. doi: 10.17470/NF-019-0011.

Di Pierro F. Assessment of Efficacy of BLIS-Producing Probiotic K12 for the Prevention of Group A Streptococcus Pha­ryngitis: a Short Communication. Probiotics and Antimicrobial Proteins. 2019. Vol. 11. P. 332-334. doi: https://doi.org/10.1007/s12602-018-9398-7.

Di Pierro F. et al. Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. Minerva Pediatrica. 2018. № 70 (3). Р. 240-245. doi: 10.23736/S0026-4946.18.05182-4.

Munck H., Jørgensen A.W., Klug T.E. Antibiotics for recurrent acute pharyngo-tonsillitis: systematic review. European Journal of Clinical Microbiology & Infectious Diseases. 2018. Vol. 37, Is. 7. P. 1221-1230.

Weber R. Pharyngitis. Primary Care: Clinics in Office Practice. 2014. Vol. 41. № 1. Р. 91-98.

Downloads

Published

2020-03-01

Issue

Vol. 8 No. 2 (2020)

Section

Original Researches

License

Copyright (c) 2020 ACTUAL INFECTOLOGY

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.